Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Executive Summary

• Satellos completed a US$57.2 million equity financing and began Nasdaq trading under “MSLE” on Feb. 6, 2026, bolstering its balance sheet for clinical development.
• The company launched two Phase 2 SAT‑3247 trials in Duchenne muscular dystrophy (DMD): BASECAMP (pediatric, placebo‑controlled) and TRAILHEAD (adult, open‑label), with first dosing already occurred and enrollment slated to finish Q3 2026.
• Interim clinical data presented at the 2026 MDA Conference showed sustained or improved grip‑strength outcomes in TRAILHEAD participants and validated a novel Regenerative Index biomarker; preclinical FSHD data also demonstrated significant muscle‑strength gains.

Key Details

• Equity Offering: Closed Feb. 9, 2026 – common shares & pre‑funded warrants for gross proceeds of US$57.2 million; Nasdaq ticker “MSLE” effective Feb. 6, 2026.
• Cash Position: $27.7 million as of Dec. 31, 2025 (down from $48.5 million YoY); runway now expected through 2027.
• Financial Performance FY 2025:
• Net loss $24.9 million ($1.70 per share), up from $20.6 million YoY.
• R&D expense $18.4 million (↑ 28% YoY) – driven by Phase 2 trial start‑up.
• G&A expense $8.0 million (↑ 33% YoY).
• BASECAMP (CL‑201) – Phase 2 Pediatric Trial:
• Global, randomized, placebo‑controlled; 51 ambulatory children (age 7–<10).
• First dose administered Feb. 12, 2026 after FDA & global clearances.
• Enrollment target to be met Q3 2026; top‑line data anticipated Q4 2026.
• Regenerative Index (RI) biomarker incorporated as exploratory endpoint.
• TRAILHEAD (LT‑001) – Phase 2 Adult Trial:
• 12‑month open‑label study; up to ~30 DMD adults ≥16 years (pending approvals).
• Four original CL‑101 participants re‑enrolled for additional ≤11 months (total ≤12 months treatment).
• Interim data after 56 days on TRAILHEAD (84 days total exposure):
  • Handgrip strength stabilized or improved vs. baseline, covering ~9–13 months cumulative exposure.
  • Preliminary gains in elbow & shoulder strength; greater improvements observed in participants with higher baseline muscle mass (creatinine).
  • FVC stable for 3/4 patients; one patient showed unexplained decline not mirrored in other functional measures.
• Preclinical FSHD Data: Presented at MDA – FLEX DUX4 model showed significant muscle‑strength enhancement over a 12‑week dosing period, supporting potential expansion of SAT‑3247 beyond DMD.
• Corporate Appointments:
• Antoinette Paone, M.S., MBA appointed Chief Development Officer & Head of Regulatory Affairs (Jan. 29, 2026).
• Mark Nawacki, MBA, CPA added to Board of Directors (Nov. 14, 2025).
• Outlook: Cash runway projected through 2027; continued enrollment in BASECAMP and expansion of TRAILHEAD expected later in 2026.

Notable Quotes

“2025 was a defining year for Satellos… we are excited by the progress across our clinical programs, including the initiation of two Phase 2 trials in Duchenne.” – Frank Gleeson, CEO

All forward‑looking statements are subject to risks and uncertainties detailed in the company’s filings.